报告题目：
Discovery of PF-4577806, a potent and selective PKC beta inhibitor for diabetic complications
报 告 人：
李辉 博士（保诺业务开发部执行总监）
时 间：
2014年9月19日下午14:00
地 点：
重庆大学虎溪校区创新药物研究中心学术报告厅
报告人简历：
Education
Dr. Li earned his bachelor’s degree in chemistry from Peking University in China and a doctorate in chemistry from the University of California. He was a founding member of the Sino-American Biomedical and Pharmaceutical Association (SABPA) in 2002 and served as SABPA (San Diego) president from 2006 to 2008. He is currently the board chairman of SABPA.
Experience
Prior to joining BioDuro, Dr. Li spent 10 years at Pfizer Global Research and Development, La Jolla Laboratories, and led research programs in a number of disease areas including oncology, metabolic diseases, antiviral and ophthalmology. He is a co-inventor of Filibuvir (PF-00868554), a hepatitis C virus polymerase inhibitor currently in Phase II clinical development, and MS-553, an oral therapy for diabetic retinopathy, which has been out-licensed to Ming Sight for development both in the U.S. and China.
